International study of MultiStem cell therapy for ischemic stroke

Trial Profile

International study of MultiStem cell therapy for ischemic stroke

Planning
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Allogeneic stem cell therapy Athersys (Primary)
  • Indications Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms MASTERS-2
  • Sponsors Athersys
  • Most Recent Events

    • 08 Aug 2017 According to an Athersys media release, design of this trial has received a Final Scientific Advice positive opinion from the European Medicines Agency. Also US FDA has granted Fast Track Designation for Multistem.
    • 28 Sep 2016 According to an Athersys media release, this trial is expected to initiate in 2017.
    • 28 Sep 2016 According to an Athersys media release, the company has received agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the design and planned analysis of this trial. The data from the trial would provide the foundation of the regulatory package to be submitted for marketing approval.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top